» Articles » PMID: 35055988

Alveolar Echinococcosis-A Challenging Task for the Hepatobiliary Surgeon

Overview
Journal Pathogens
Date 2022 Jan 21
PMID 35055988
Authors
Affiliations
Soon will be listed here.
Abstract

(1) Background: Alveolar echinococcosis (AE) is an ultimately fatal disease, whose only curative treatment is surgery. Due to its late presentation extended liver resections are often necessary. The true benefit of extensive surgery has yet to be established; (2) Methods: We present a single center experience of 33 cases of Echinococcus multilocularis that have been treated at a high-volume hepatobiliary surgery center between 2004 and 2021. (3) Results: Of the 33 patients 24 patients underwent major liver resection (73%). In addition to the liver resection patients frequently underwent complex extrahepatic procedures such as lymphadenectomy (n = 21, 61%), vascular resections and reconstructions (n = 9, 27%) or resections and reconstruction of the extrahepatic bile duct (n = 11, 33%). Seven patients suffered from ≥ grade III complications (21%). Complete resection was achieved in 17 patients. Fourteen patients had R1 resections and two had macroscopic parasitic remnant (R2). Progressive disease was reported in three patients (The two R2 patients and one R1 resected patient). At a median follow-up of 54 months no mortality has occurred in our cohort; (4) Conclusions: Liver resection remains the gold standard for AE. Even in extensive disease the combination of complex resection and perioperative benzimidazoles can achieve favorable long-term outcomes.

Citing Articles

Advances in Novel Diagnostic Techniques for Alveolar Echinococcosis.

Liu H, Xie Y, An X, Xu D, Cai S, Chu C Diagnostics (Basel). 2025; 15(5).

PMID: 40075832 PMC: 11898896. DOI: 10.3390/diagnostics15050585.


Value of intralesional and perilesional radiomics for predicting the bioactivity of hepatic alveolar echinococcosis.

Zhang S, Hou J, Xia W, Zhao Z, Xu M, Li S Front Oncol. 2024; 14:1389177.

PMID: 38993649 PMC: 11236607. DOI: 10.3389/fonc.2024.1389177.


[Treatment concepts for hepatic echinococcosis].

Denzinger M, Nasir N, Steinkraus K, Michalski C, Huttner F, Traub B Chirurgie (Heidelb). 2023; 94(6):560-570.

PMID: 36853342 DOI: 10.1007/s00104-023-01825-w.

References
1.
Torgerson P, Schweiger A, Deplazes P, Pohar M, Reichen J, Ammann R . Alveolar echinococcosis: from a deadly disease to a well-controlled infection. Relative survival and economic analysis in Switzerland over the last 35 years. J Hepatol. 2008; 49(1):72-7. DOI: 10.1016/j.jhep.2008.03.023. View

2.
Ammann R, Hoffmann A, Eckert J . [Swiss study of chemotherapy of alveolar echinococcosis--review of a 20-year clinical research project]. Schweiz Med Wochenschr. 1999; 129(8):323-32. View

3.
Ammann R . Improvement of liver resectional therapy by adjuvant chemotherapy in alveolar hydatid disease. Swiss Echinococcosis Study Group (SESG). Parasitol Res. 1991; 77(4):290-3. DOI: 10.1007/BF00930903. View

4.
Aubin J, Bressan A, Grondin S, Dixon E, MacLean A, Gregg S . Assessing resectability of colorectal liver metastases: How do different subspecialties interpret the same data?. Can J Surg. 2018; 61(4):251-256. PMC: 6066391. View

5.
Brunetti E, Kern P, Vuitton D . Expert consensus for the diagnosis and treatment of cystic and alveolar echinococcosis in humans. Acta Trop. 2009; 114(1):1-16. DOI: 10.1016/j.actatropica.2009.11.001. View